Charles Queenan III

Charles Queenan III is a seasoned executive in the biotechnology and life sciences sectors, boasting extensive experience as Co-Founder and CEO of Forkhead BioTherapeutics Inc, where a transformational oral therapy for insulin-dependent diabetes is being developed. Previously, Charles founded and served as Managing Director of Strategic Resolve LLC, delivering strategic consultancy to life sciences organizations. Notable roles include Partner at T1D Innovations LLC, Managing Partner at the Diabetes Investment Fund LLC, and Senior Vice President at JDRF. Charles's career also includes significant positions at Amaranth Bio Inc. and a solid foundation in consulting at PHB Hagler Bailly. An educator and researcher early in their career, Charles holds advanced degrees in Finance and Chemical Engineering from prestigious institutions including Carnegie Mellon University and Dartmouth College.